Skip to main content
. 2022 Aug 9;41(2):154–162. doi: 10.2337/cd22-0016

TABLE 3.

Efficacy of Semglee and Abasaglar Compared With Reference Insulin Glargine (35,38)

Study Characteristics/Findings INSTRIDE 2 Trial ELEMENT 2 Trial
Population Type 2 diabetes (n = 560) Type 2 diabetes (n = 756)
Study length, weeks 24 24
Treatment Semglee Abasaglar
Mean change in A1C from baseline to week 24, % −0.60 with Semglee versus −0.66 with reference insulin glargine −1.29 with Abasaglar versus −1.34% with reference insulin glargine
Hypoglycemia rate (total), % 22.5 versus 19.9 21.3 versus 22.3
Immunogenicity, % 25.4 versus 27.0 15 versus 11